Colleges
Jack Tan
DPhil, BSc (Hons)
RDM Principal Investigator
Dr Tan is a Principal Investigator at the MRC Translational Immune Discovery Unit.
His research focuses developing next-generation protein nanoparticle-based vaccines and antibody therapeutics against infectious diseases. He is particularly interested in understanding how the architecture of protein nanoparticle vaccines influences their immunogenicity, as well as investigating mucosal vaccine immunity to improve vaccine design against respiratory pathogens such as coronavirus.
Dr Tan is part of an international consortium (Oxford-Caltech-CPI-Ingenza) funded by the Coalition of Epidemics Preparedness Innovations (CEPI) to develop novel a pan-sarbecovirus (SARS-like betacoronavirus) nanoparticle vaccine. He is also a Career Development Fellow at the Chinese-Academy of Medical Sciences-Oxford Institute, and a Fellow by Special Election at St Edmund Hall.
Recent publications
-
Publisher Correction: The molecular reach of antibodies crucially underpins their viral neutralisation capacity
Huhn A. et al, (2025), Nature Communications, 16
-
A locally administered single-cycle influenza vaccine expressing a non-fusogenic stabilized hemagglutinin stimulates strong T-cell and neutralizing antibody immunity.
Sadler HL. et al, (2025), J Virol
-
The molecular reach of antibodies crucially underpins their viral neutralisation capacity
DUSHEK O., (2024), Nature Communications
-
Development of a recombinant non-replicating Newcastle disease virus.
Cheow P-S. et al, (2024), Avian Pathol, 1 - 9